Published in Neurosurgery on November 01, 1999
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets (2012) 1.01
Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther (2005) 0.95
Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer (2006) 0.94
Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther (2009) 0.88
Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis. Neuro Oncol (2008) 0.88
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
Current and Future Gene Therapy for Malignant Gliomas. J Biomed Biotechnol (2003) 0.86
Gene therapy for malignant glioma. Mol Cell Ther (2014) 0.83
The Treatment of Malignant Gliomas. Curr Treat Options Neurol (2005) 0.79
New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J Immunother Cancer (2015) 0.75
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg (2001) 11.58
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg (1996) 3.75
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res (1996) 2.76
An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg (2000) 2.50
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene (2006) 2.37
Aggressive meningeal tumors: review of a series. J Neurosurg (1995) 2.26
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol (1996) 2.04
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene (2007) 1.98
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res (1999) 1.95
Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology (2002) 1.89
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res (1999) 1.88
Management of intracranial plasmacytoma. J Neurosurg (1995) 1.81
Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology (2006) 1.75
Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst (1999) 1.71
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res (2001) 1.68
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res (1999) 1.66
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol (2000) 1.66
Surgical treatment of multiple brain metastases. J Neurosurg (1993) 1.61
Response and progression in recurrent malignant glioma. Neuro Oncol (1999) 1.57
Transthoracic vertebrectomy for metastatic spinal tumors. J Neurosurg (1998) 1.55
Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol (2001) 1.53
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res (1998) 1.52
Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol (1991) 1.47
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology (1998) 1.46
Use of intraoperative ultrasound for localizing tumors and determining the extent of resection: a comparative study with magnetic resonance imaging. J Neurosurg (1996) 1.44
Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res (1981) 1.44
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys (1995) 1.41
The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol (1997) 1.40
Spinal cord lesion after epidural anesthesia diagnosed by motor evoked potentials. Muscle Nerve (1993) 1.38
The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care (1997) 1.37
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol (2000) 1.35
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 1.28
Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol (2000) 1.27
Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res (2000) 1.27
Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res (1996) 1.26
External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys (1997) 1.25
Acute spontaneous subdural hematoma. Surg Neurol (1984) 1.22
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res (2000) 1.22
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res (1996) 1.21
Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer (1995) 1.21
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer (2000) 1.19
A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes (2000) 1.18
Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med (1998) 1.18
Dandy-Walker syndrome. Clinical analysis of 23 cases. J Neurosurg (1981) 1.17
Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res (1994) 1.16
Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res (1993) 1.16
Volumetric measurement of brain tumors from MR imaging. J Neurooncol (1998) 1.15
Analysis of the functional role of chromosome 10 loss in human glioblastomas. Cancer Res (1993) 1.15
Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene (2001) 1.14
Postoperative mutism in neurosurgery. Report of two cases. J Neurosurg (1994) 1.13
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res (1994) 1.13
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost (2010) 1.12
An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. J Cell Biol (1983) 1.11
Intraoperative chemical hemostasis in neurosurgery. Neurosurgery (1986) 1.10
Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res (1993) 1.09
Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res (2001) 1.07
Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst (1997) 1.07
Pulsed-field gel electrophoretic analysis of DNA double-strand breaks in mammalian cells using photostimulable storage phosphor imaging. Int J Radiat Biol (1994) 1.07
Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene (1997) 1.06
In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene (1997) 1.05
Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res (1982) 1.05
Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res (2000) 1.05
Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis (1995) 1.05
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res (1999) 1.04
Effect of cell-cell interactions on drug sensitivity and growth of drug-sensitive and -resistant tumor cells in spheroids. Science (1984) 1.04
Surgical resection of intrinsic insular tumors: complication avoidance. J Neurosurg (2001) 1.04
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther (2008) 1.03
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol (2001) 1.03
Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res (1989) 1.02
Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis (1995) 1.01
Intracranial osteolytic malignant meningiomas appearing as extracranial soft-tissue masses. Neurosurgery (1992) 1.01
Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol (2000) 1.01
Observations regarding DNA replication sites in human cells in vivo following infusions of iododeoxyuridine and bromodeoxyuridine. Cell Prolif (1991) 1.00
Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol (1997) 0.99
Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol (1993) 0.99
Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol (1985) 0.99
Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors. J Neurooncol (2001) 0.98
The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery (1997) 0.98
Expression of an altered epidermal growth factor receptor by human glioblastoma cells. Cancer Res (1988) 0.98
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res (1990) 0.98
Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol (2001) 0.98
Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem (2001) 0.97
Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res (2001) 0.97
Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett (1996) 0.96
Potential methods for predicting tumor radiocurability. Int J Radiat Oncol Biol Phys (1986) 0.96
Effects of radiation on the levels of MMP-2, MMP-9 and TIMP-1 during morphogenic glial-endothelial cell interactions. Int J Cancer (2000) 0.96
Choroid plexus cyst and chordoid glioma. Report of two cases. Neurosurg Focus (2001) 0.96
Surgical resection of calvarial metastases overlying dural sinuses. Neurosurgery (2001) 0.96
Lesions of the calvaria: surgical experience with 42 patients. Ann Surg Oncol (1997) 0.95
The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol (1997) 0.95
Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis (1996) 0.95
Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res (1997) 0.95
Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res (2000) 0.95